Asset Details
Do you wish to reserve the book?
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
Do you wish to request the book?
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
2009
Overview
Our aging society is confronted with a dramatic increase of patients suffering from tauopathies, which include Alzheimer disease and certain frontotemporal dementias. These disorders are characterized by typical neuropathological lesions including hyperphosphorylation and subsequent aggregation of TAU protein and neuronal cell death. Currently, no mechanism-based cures are available. We generated fluorescently labeled TAU transgenic zebrafish, which rapidly recapitulated key pathological features of tauopathies, including phosphorylation and conformational changes of human TAU protein, tangle formation, neuronal and behavioral disturbances, and cell death. Due to their optical transparency and small size, zebrafish larvae are well suited for both in vivo imaging and drug development. TAU-induced neuronal cell death was imaged by time-lapse microscopy in vivo. Furthermore, we used this zebrafish model to identify compounds targeting the TAU kinase glycogen synthase kinase 3beta (GSK3beta). We identified a newly developed highly active GSK3beta inhibitor, AR-534, by rational drug design. AR-534 reduced TAU phosphorylation in TAU transgenic zebrafish. This transgenic zebrafish model may become a valuable tool for further studies of the neuropathology of dementia.
Publisher
American Society for Clinical Investigation
Subject
/ Animals, Genetically Modified
/ Drug Evaluation, Preclinical - methods
/ Embryo, Nonmammalian - abnormalities
/ Embryo, Nonmammalian - drug effects
/ Embryo, Nonmammalian - metabolism
/ Embryo, Nonmammalian - pathology
/ Enzyme Inhibitors - chemistry
/ Enzyme Inhibitors - pharmacokinetics
/ Enzyme Inhibitors - pharmacology
/ Glycogen Synthase Kinase 3 - antagonists & inhibitors
/ Glycogen Synthase Kinase 3 - chemistry
/ Glycogen Synthase Kinase 3 - genetics
/ Glycogen Synthase Kinase 3 beta
/ Humans
/ Luminescent Proteins - genetics
/ Luminescent Proteins - metabolism
/ Motor Neurons - drug effects
